In 85% of uveal melanomas (UM) with GNAQ/GNA11 mutations, which overexpress the transcription factors MITF and SOX10 and over-interact with the BAF complex, FHD-286 inhibits SMARCA2/SMARCA4, leading to loss of accessibility of the SOX10 and MITF transcription factor binding sites, and suppression of the SOX10 and MITF dependent gene (GNAQ/GNA11) expression and preclinical data showed that FHD-286 dose-dependently inhibited tumor growth (133, 134). Here, SMARCA2 is linked to neoplasm.